Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co., Ltd.
Your view on CHGCY
Overview
What the company does, where it operates, and who runs it.
About Chugai Pharmaceutical Co., Ltd.
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Osamu Okuda
- Headquarters
- Nihonbashi Mitsui Tower, Tokyo, JP
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Osamu Okuda
- Headquarters
- Nihonbashi Mitsui Tower, Tokyo, JP
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally.
The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng.
It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia.
The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Chugai Pharmaceutical Co., Ltd., and the rating behind it. CHGCY last traded at $33.41, 22.4× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Chugai Pharmaceutical Co., Ltd.. Starting points for Chugai Pharmaceutical Co., Ltd.: P/E 22.4, EPS $143.22, beta 0.40 — an Drug Manufacturers - General name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Chugai Pharmaceutical Co., Ltd.. Chugai Pharmaceutical Co., Ltd. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Chugai Pharmaceutical Co., Ltd.. Trailing twelve-month EPS for Chugai Pharmaceutical Co., Ltd. stands at $143.22. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Chugai Pharmaceutical Co., Ltd.. Chugai Pharmaceutical Co., Ltd. has reported as a listed company since 2012. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Chugai Pharmaceutical Co., Ltd. valued side by side against its closest peers. Chugai Pharmaceutical Co., Ltd. is measured against Drug Manufacturers - General peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Chugai Pharmaceutical Co., Ltd., and how their positions are changing. At a $109.97B market value, institutional positions materially move Chugai Pharmaceutical Co., Ltd.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Chugai Pharmaceutical Co., Ltd. executives and directors. Shares of Chugai Pharmaceutical Co., Ltd. have traded between $19.50 and $34.30 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Chugai Pharmaceutical Co., Ltd.. Chugai Pharmaceutical Co., Ltd. is a $109.97B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Chugai Pharmaceutical Co., Ltd.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Chugai Pharmaceutical Co., Ltd.. Coverage tracks Chugai Pharmaceutical Co., Ltd. within Drug Manufacturers - General (Healthcare). Press releases and market coverage, newest first.